Recon: FDA approves Gilead’s Veklury for young children; Nektar to lay off 70% of its staff after key drug failure
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy